US Patent

US12448366 — Solid forms of pralsetinib

Composition of Matter · Assigned to Rigel Pharmaceuticals Inc · Expires 2042-07-07 · 16y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects various crystalline solid forms and salt forms of the free base pralsetinib.

USPTO Abstract

The compound cis)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4 methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide can be prepared as a free base in various crystalline solid forms, and in various salt forms each having one or more solid forms.

Drugs covered by this patent

Patent Metadata

Patent number
US12448366
Jurisdiction
US
Classification
Composition of Matter
Expires
2042-07-07
Drug substance claim
Yes
Drug product claim
No
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.